Securities code: 600976 securities abbreviation: Jianmin Pharmaceutical Group Co.Ltd(600976) Announcement No.: 2022-005 Jianmin Pharmaceutical Group Co.Ltd(600976)
On the reduction of shares of the company by controlling shareholders and persons acting in concert
More than 1% of suggestive announcements
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The change in equity is that the controlling shareholders of the company and their persons acting in concert reduced their shares of the company through block trading, and did not touch the tender offer.
This equity change will not lead to changes in the controlling shareholders and actual controllers of the company.
After this equity change, the proportion of the company’s shares held by the company’s controlling shareholders and their persons acting in concert increased from
29.41% decreased to 27.45%, and the proportion of changes in equity was 1.96%.
Jianmin Pharmaceutical Group Co.Ltd(600976) (hereinafter referred to as “the company”) received the notification letter on reducing the proportion of Jianmin Pharmaceutical Group Co.Ltd(600976) shares by more than 1% from Huali Group Co., Ltd., the indirect controlling shareholder of the company, on January 14, 2022. The controlling shareholders and persons acting in concert of the company have cumulatively reduced 3 million shares of the company through block trading, accounting for 1.96% of the total share capital of the company. The relevant changes in equity are announced as follows: I. Basic information of this change in equity
(I) information disclosure obligor
1. Huali Pharmaceutical Group Co., Ltd
Information disclosure obligor: Huali Pharmaceutical Group Co., Ltd
Address: No. 181, Wuchang Avenue, Yuhang District, Hangzhou, Zhejiang
Change time of Equity: August 16, 2021
Change method change date share nature share reduction proportion equity change details
Block trading on August 16, 2021, 147000 tradable shares were sold without restriction, 0.96%
2. Huali Group Co., Ltd
Information disclosure obligor: Huali Group Co., Ltd
Address: No. 181, Wuchang Avenue, Yuhang District, Hangzhou, Zhejiang
Change time of Equity: January 14, 2022
Change method change date share nature share reduction proportion equity change details
Block trading 1530000 tradable shares on January 14, 2022 1.00%
The above information disclosure obligor Huali Pharmaceutical Group Co., Ltd. is the controlling shareholder of the company and Huali Pharmaceutical Group
Ltd. is a wholly-owned subsidiary of Huali Group Co., Ltd.
(II) shares held by information disclosure obligors before and after the equity change
Shares held before this change shares held after this change
Name of shareholder and nature of shares
Proportion of shares in total share capital proportion of shares in total share capital
Huali medicine collection
Unlimited tradable shares 38484073 shares 25.09% 37014073 shares 24.13% Huali group shares of Group Co., Ltd
6628541 non tradable shares 4.32% 5098541 shares 3.32%
Co., Ltd
Total 45112614 shares 29.41%, 42112614 shares 27.45%
All shares involved in this equity change enjoy voting rights, and there are no voting rights such as delegation or restriction of voting rights
The transfer of interest is restricted or restricted. This equity change does not violate the securities law and the income of listed companies
Relevant provisions of laws and regulations such as the measures for the administration of share purchase and the business rules of Shanghai Stock Exchange and their relevant commitments
No.
2、 Follow up matters involved
1. This equity change is a reduction, which is based on the controlling shareholders of the company and their persons acting in concert according to their own funds
Arrangement, not involving the source of funds;
2. This equity change will not lead to changes in the controlling shareholders and their actual controllers of the company;
3. This equity change does not involve the disclosure of the simplified equity change report by the information disclosure obligor.
It is hereby announced.
Jianmin Pharmaceutical Group Co.Ltd(600976)
Board of directors
January 16, 2022
